MB Therapeutics

MB Therapeutics is a private, pre-revenue platform company pioneering the application of 3D printing to create personalized medicines. Its core offering is an integrated system for pharmacies and pharmaceutical manufacturers to produce tailored solid-dose medications with customizable dosages, forms, and multi-drug combinations. The company leverages over eight years of expertise and has established partnerships with major pharmaceutical players like Sanofi, positioning itself at the intersection of digital manufacturing and precision healthcare. Its value proposition centers on improving treatment adherence, accelerating drug development, and enabling decentralized, on-demand medication production.

Integrated pharmaceutical 3D printing platform comprising proprietary GMP printers, specialized dosage design software, and material development services for creating personalized solid-dose medications with customizable dosage, form, and drug combinations.

The field of pharmaceutical 3D printing is emerging but competitive, with other startups (e.g., FabRx, Triastek) and academic consortia developing similar technologies. MB Therapeutics differentiates through its integrated platform approach, focus on multiple printing technologies, and its evident early partnerships with large pharma.